- Molecular NamePenicillamine
- Synonymbeta-Thiovaline; beta,beta-Dimethylcysteine; D-Mercaptovaline; D-Penamine; D-Penicilamine; D-Penicillamine; D-Penicyllamine; Dimethylcysteine; L-Penicillamine; PCA; Penicilamina [INN-Spanish]; Penicillamin; Penicillamina [DCIT]; Penicillaminum [INN-Latin]; Penicilllamine
- Weight149.214
- Drugbank_IDDB00859
- ACS_NO52-67-5
- Show 3D model
- LogP (experiment)-1.78
- LogP (predicted, AB/LogP v2.0)-1.83
- pka1.8, 7.9, 10.5
- LogD (pH=7, predicted)-1.84
- Solubility (experiment)111 mg/mol
- LogS (predicted, ACD/Labs)(ph=7)0.31
- LogSw (predicted, AB/LogsW2.0)78.84
- Sw (mg/ml) (predicted, ACD/Labs)304.44
- No.of HBond Donors3
- No.of HBond Acceptors3
- No.of Rotatable Bonds2
- TPSA102.12
- StatusFDA approved
- AdministrationN/A
- PharmacologyA pharmaceutical of the chelator class.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability50.0
- Protein binding90.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic
- Half life2~6 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most common adverse events to Penicillamine are vomiting, anorexia, fever, diarrhea, lethargy, and rash.
- LD50 (rat)N/A
- LD50 (mouse)N/A